Literature DB >> 11807324

Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor.

Guiseppe Murdaca, Antonio Campelli, Maurizio Setti, Francesco Indiveri, Francesco Puppo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11807324     DOI: 10.1097/00002030-200201250-00029

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  5 in total

1.  AIDS-associated Kaposi's sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South Africa.

Authors:  Kathryn M Chu; Gcina Mahlangeni; Sarah Swannet; Nathan P Ford; Andrew Boulle; Gilles Van Cutsem
Journal:  J Int AIDS Soc       Date:  2010-07-08       Impact factor: 5.396

2.  Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy.

Authors:  Mary Cianfrocca; Sandra Lee; Jamie Von Roenn; Anil Tulpule; Bruce J Dezube; David M Aboulafia; Richard F Ambinder; Jeannette Y Lee; Susan E Krown; Joseph A Sparano
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

Review 3.  Liposomal daunorubicin as treatment for Kaposi's sarcoma.

Authors:  Christin E Petre; Dirk P Dittmer
Journal:  Int J Nanomedicine       Date:  2007

4.  Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy.

Authors:  V Martinez; E Caumes; L Gambotti; H Ittah; J-P Morini; J Deleuze; I Gorin; C Katlama; F Bricaire; N Dupin
Journal:  Br J Cancer       Date:  2006-04-10       Impact factor: 7.640

5.  Splenic Kaposi's sarcoma in a human immunodeficiency virus-negative patient: A case report.

Authors:  Chuan-Jie Zhao; Guang-Zhen Ma; Yan-Jun Wang; Jin-Hong Wang
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.